0K1R Stock Chart & Stats
$19.42
$0.05(0.26%)
At close: 4:00 PM EDT
$19.42
$0.05(0.26%)
Day’s Range― - ―
52-Week Range$13.25 - $34.31
Previous CloseN/A
Volume549.00
Average Volume (3M)1.48K
Market Cap
$2.64B
Enterprise Value$1.34B
Total Cash (Recent Filing)$981.53M
Total Debt (Recent Filing)$242.88M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 04, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding113,292,270
10 Day Avg. Volume685
30 Day Avg. Volume1,479
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue18.86
Enterprise Value/Gross Profit18.94
Enterprise Value/Ebitda-3.65
Forecast
1Y Price Target
$34.11Price Target Upside75.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.93
Revenue Forecast (FY)$24.38M
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionThe substantial revenue step-up demonstrates meaningful progress from Viridian’s historically limited base and provides evidence of increasing commercial or collaboration activity. Sustaining this level of revenue could improve development funding capacity and support broader pipeline advancement over the next several quarters.
Balance Sheet FlexibilitySizable equity combined with low leverage gives Viridian a stronger financial foundation than many development-stage companies. This flexibility can help fund clinical programs, absorb development setbacks, and preserve strategic options while the company works toward regulatory and commercial milestones.
Funding And Manufacturing ReadinessThe capital raise strengthens resources for pipeline execution, while full loan repayment reduces future financing obligations. The WuXi manufacturing agreement also supports potential commercialization readiness, giving Viridian a more developed operational base as programs advance through clinical development.
Bears Say
Persistent Operating LossesThe scale of ongoing losses remains a major fundamental weakness because revenue growth has not translated into operating breakeven. Continued heavy expense requirements could consume capital rapidly and make future clinical progress increasingly dependent on additional financing or successful commercialization.
High Cash BurnLarge recurring cash outflows show that Viridian is not yet self-funding its operations despite the stronger revenue base. Persistent cash burn reduces the duration of existing resources, limits flexibility in allocating capital, and increases the importance of future financing or milestone-driven cash inflows.
No Approved Commercial ProductWithout an approved product, Viridian lacks a durable recurring-sales foundation and remains dependent on clinical success, regulatory approval, and eventual commercialization. This creates substantial execution risk because future revenue generation depends on converting investigational programs into approved therapies.
Viridian Therapeutics News
0K1R FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest share price was $13.25 and its highest was $34.31 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $2.64B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 7 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Aug 06, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$1.035 by -$0.015.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 113,292,270 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$1.035. Following the earnings report the stock price went up 5.449%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in GB:0K1R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.11 (75.65% Upside)
$34.11 (75.65% Upside)
Blogger Sentiment
Bullish
GB:0K1R Sentiment 60%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $348.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.32%
12-Months-Change
Fundamentals
Return on Equity
-61.35%
Trailing 12-Months
Asset Growth
88.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
0K1R Stock 12 Month Forecast
Average Price Target
$34.11
▲(75.65% Upside)
Technical Analysis
Celldex
―
Ultragenyx Pharmaceutical
―
MoonLake Immunotherapeutics
―
Vera Therapeutics
―
Zenas BioPharma, Inc.
―